BCM
IMVT icon

BCK Capital Management’s Immunovant IMVT Stock Holding History

BCK Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-54,293
Closed -$303K – 79
2022
Q3 		$303K Hold
54,293
– – 0.22% 62
2022
Q2 		$212K Hold
54,293
– – 0.16% 67
2022
Q1 		$299K Hold
54,293
– – 0.18% 105
2021
Q4 		$463K Buy
54,293
+834
+2% +$6.88K 0.31% 76
2021
Q3 		$465K Buy
53,459
+13,222
+33% +$119K 0.28% 93
2021
Q2 		$425K Buy
40,237
+8,910
+28% +$124K 0.21% 102
2021
Q1 		$502K Buy
+31,327
New +$826K 0.28% 96

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BCK Capital Management's IMVT Position: Q4 2022 in Review

BCK Capital Management sold out of Immunovant (IMVT) in Q4 2022, closing a stake of 54,293 shares — an estimated $303K sold.

BCK Capital Management first reported a position in IMVT in Q1 2021 and held it in 7 quarters. The position peaked at $502K in Q1 2021. 133 funds tracked by Wall St. Rank hold IMVT as of Q4 2022.

  • BCK Capital Management reported no remaining Immunovant position as of Q4 2022 after selling out during the quarter.
  • BCK Capital Management sold 54,293 Immunovant shares in Q4 2022, an estimated $303K.
  • BCK Capital Management first reported a position in Immunovant in Q1 2021 and held it in 7 quarters.
  • BCK Capital Management's Immunovant position peaked at $502K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Immunovant as of Q4 2022.

Based on BCK Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.